Stephen Austin - Imprimis Pharmaceuticals Independent Director
Director
Mr. Stephen G. Austin, CPA, is Independent Director of Imprimis Pharmaceuticals, Inc., since July 2012. He has served as our director since July 2012. He was a Partner in Swenson Advisors, LLP, a regional accounting firm, since May 1998 and has served as Managing Partner since October 2006. At Swenson Advisors, Mr. Austin manages assurance, SarbanesOxley and other business consulting for public and private companies with a focus on technology, manufacturing, service, real estate, social media and nonprofit organizations. Prior to joining Swenson Advisors, Mr. Austin accumulated over 22 years of experience as an audit partner with Price Waterhouse LLP, where he worked from 1976 to 1996, and with McGladrey Pullen, LLP, where he worked from 1996 to 1998, serving both public and private companies. He serves as a board member or advisory board member for various notforprofit foundations, associations and public service organizations in the United States, is on the global board of directors of Integra International, an international association of accounting firms, and served as a director on the board of Avanir Pharmaceuticals, Inc. from March 2003 to December 2012, where he also served on the audit committee and compensation committee. In 2004, Mr. Austin published a book on business ethics entitled Rise of the New Ethics Class, and in 2005 and 2006 he published articles in Asia discussing The SarbanesOxley Act of 2002. Mr. Austin has also authored articles for the American Institute of CPAs, including the Journal of Accountancy since 2012.
Age | 61 |
Tenure | 12 years |
Professional Marks | MBA |
Phone | 858-704-4040 |
Web | http://www.imprimisrx.com |
Imprimis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (11.94) % which means that it has lost $11.94 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (153.09) %, meaning that it created substantial loss on money invested by shareholders. Imprimis Pharmaceuticals' management efficiency ratios could be used to measure how well Imprimis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 15.28 M in liabilities with Debt to Equity (D/E) ratio of 343.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Imprimis Pharmaceuticals has a current ratio of 1.11, suggesting that it may not be capable to disburse its financial obligations when due. Debt can assist Imprimis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Imprimis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Imprimis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Imprimis to invest in growth at high rates of return. When we think about Imprimis Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Jeanine Lioko | Barrick Gold Corp | 52 | |
Michael Evans | Barrick Gold Corp | 60 | |
Brett Harvey | Barrick Gold Corp | 67 | |
Ernie Thrasher | Barrick Gold Corp | 61 | |
Neil Simpkins | Summit Materials | 51 | |
Safiatou BaNDaw | Barrick Gold Corp | 64 | |
Andrew Quinn | Barrick Gold Corp | 66 | |
Brian Greenspun | Barrick Gold Corp | 73 | |
Steven Shapiro | Barrick Gold Corp | 65 | |
Anne Wade | Summit Materials | 48 | |
Kadri Dagdelen | Barrick Gold Corp | 60 | |
Karl Voltaire | Barrick Gold Corp | 63 | |
Pablo Marcet | Barrick Gold Corp | 53 | |
Robert Prichard | Barrick Gold Corp | 68 | |
Steven Wunning | Summit Materials | 70 | |
Anne Cooney | Summit Materials | 61 | |
Jemaluddin Kassum | Barrick Gold Corp | 68 | |
John Murphy | Summit Materials | 70 | |
Graham Clow | Barrick Gold Corp | 66 | |
Anthony Munk | Barrick Gold Corp | 57 | |
Olivia Kirtley | Barrick Gold Corp | 66 |
Management Performance
Return On Equity | -153.09 | |||
Return On Asset | -11.94 |
Imprimis Pharmaceuticals Leadership Team
Elected by the shareholders, the Imprimis Pharmaceuticals' board of directors comprises two types of representatives: Imprimis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imprimis. The board's role is to monitor Imprimis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Imprimis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imprimis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Nelson, Director | ||
Robert Kammer, Chairman of the Board | ||
Clayton Edwards, COO | ||
John Saharek, Chief Commercial Officer | ||
Anthony Principi, Independent Director | ||
Andrew Boll, Vice President - Accounting and Financial Reporting | ||
Mark Baum, CEO, Director | ||
Richard Lindstrom, Director | ||
Stephen Austin, Independent Director |
Imprimis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Imprimis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -153.09 | |||
Return On Asset | -11.94 | |||
Profit Margin | (16.81) % | |||
Operating Margin | (13.94) % | |||
Current Valuation | 120.54 M | |||
Shares Outstanding | 23.28 M | |||
Shares Owned By Insiders | 7.16 % | |||
Shares Owned By Institutions | 23.26 % | |||
Number Of Shares Shorted | 231.01 K | |||
Price To Earning | (2.02) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Imprimis Stock
If you are still planning to invest in Imprimis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Imprimis Pharmaceuticals' history and understand the potential risks before investing.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |